PharmaWire has reported on the tafamidis patent trial ahead of its scheduled court date on 27 April. Analysts have pointed to early signs that may be shaping expectations for Pfizer (NYSE: PFE), BridgeBio (NASDAQ: BBIO) and the broader ATTR-CM market.
Nuvectis Chairman & CEO Ron Bentsur: “2024 is shaping up to be a potentially transformational year for Nuvectis with several clinical data updates expected in the second half of the year.”
Unlocking Market Potential: Innocan Pharma's Breakthrough Cream Shows Promise in Diabetic Foot Care
OcyonBio CDMO welcomes cell and gene therapy expert Robert Salcedo who brings over 20 years of expertise in the areas of CMC, operations, and supply chain management and has served in multi-billion-dollar companies operating in biotech, vaccines, and pharmaceutical markets.
Meet SciSparc Ltd., the biotech disruptor with potential pipeline revenues of about $490,926,545
Multicenter 'collaboratory' will focus on the use of artificial intelligence to improve long-term health, independence for older people
Producing medicines for the United States, the plant features innovative technologies and advancements in sustainability
